The phosphorylation-dependent regulation of nuclear SREBP1 during mitosis links lipid metabolism and cell growth

References

• Brown MS, Goldstein JL. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc Natl Acad Sci U S A 1999; 96:11041-8; PMID:10500120; http://dx.doi.org/10.1073/pnas.96.20.11041
   PubMed Web of Science ®Google Scholar
• Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109:1125-31; PMID:11994399; http://dx.doi.org/10.1172/JCI0215593
   PubMed Web of Science ®Google Scholar
• Goldstein JL, DeBose-Boyd RA, Brown MS. Protein sensors for membrane sterols. Cell 2006; 124:35-46; PMID:16413480; http://dx.doi.org/10.1016/j.cell.2005.12.022
   PubMed Web of Science ®Google Scholar
• Osborne TF, Espenshade PJ. Evolutionary conservation and adaptation in the mechanism that regulates SREBP action: what a long, strange tRIP it's been. Genes Dev 2009; 23:2578-91; PMID:19933148; http://dx.doi.org/10.1101/gad.1854309
   PubMed Web of Science ®Google Scholar
• Brown MS, Goldstein JL. Cholesterol feedback: from Schoenheimer's bottle to Scap's MELADL. J Lipid Res 2009; 50(Suppl):S15-27; PMID:18974038
   PubMed Web of Science ®Google Scholar
• Shimomura I, Shimano H, Horton JD, Goldstein JL, Brown MS. Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells. J Clin Invest 1997; 99:838-45; PMID:9062340; http://dx.doi.org/10.1172/JCI119247
   PubMed Web of Science ®Google Scholar
• Hirano Y, Yoshida M, Shimizu M, Sato R. Direct demonstration of rapid degradation of nuclear sterol regulatory element-binding proteins by the ubiquitin-proteasome pathway. J Biol Chem 2001; 276:36431-7; PMID:11477106; http://dx.doi.org/10.1074/jbc.M105200200
   PubMed Web of Science ®Google Scholar
• Bengoechea-Alonso MT, Ericsson J. A phosphorylation cascade controls the degradation of active SREBP1. J Biol Chem 2009; 284:5885-95; PMID:19126544; http://dx.doi.org/10.1074/jbc.M807906200
   PubMed Web of Science ®Google Scholar
• Sundqvist A, Bengoechea-Alonso MT, Ye X, Lukiyanchuk V, Jin J, Harper JW, Ericsson J. Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF(Fbw7). Cell Metab 2005; 1:379-91; PMID:16054087; http://dx.doi.org/10.1016/j.cmet.2005.04.010
   PubMed Web of Science ®Google Scholar
• Cremona CA, Sancho R, Diefenbacher ME, Behrens A. Fbw7 and its counteracting forces in stem cells and cancer: Oncoproteins in the balance. Semin Cancer Biol 2016; 36:52-61; PMID:26410034; http://dx.doi.org/10.1016/j.semcancer.2015.09.006
   PubMed Web of Science ®Google Scholar
• Davis RJ, Welcker M, Clurman BE. Tumor suppression by the Fbw7 ubiquitin ligase: mechanisms and opportunities. Cancer Cell 2014; 26:455-64; PMID:25314076; http://dx.doi.org/10.1016/j.ccell.2014.09.013
   PubMed Web of Science ®Google Scholar
• Xu W, Taranets L, Popov N. Regulating Fbw7 on the road to cancer. Semin Cancer Biol 2016; 36:62-70; PMID:26459133; http://dx.doi.org/10.1016/j.semcancer.2015.09.005
   PubMed Web of Science ®Google Scholar
• Bengoechea-Alonso MT, Punga T, Ericsson J. Hyperphosphorylation regulates the activity of SREBP1 during mitosis. Proc Natl Acad Sci U S A 2005; 102:11681-6; PMID:16081540; http://dx.doi.org/10.1073/pnas.0501494102
   PubMed Web of Science ®Google Scholar
• Bengoechea-Alonso MT, Ericsson J. Cdk1/cyclin B-mediated phosphorylation stabilizes SREBP1 during mitosis. Cell Cycle 2006; 5:1708-18; PMID:16880739; http://dx.doi.org/10.4161/cc.5.15.3131
   PubMed Web of Science ®Google Scholar
• Bruinsma W, Raaijmakers JA, Medema RH. Switching Polo-like kinase-1 on and off in time and space. Trends Biochem Sci 2012; 37:534-42; PMID:23141205; http://dx.doi.org/10.1016/j.tibs.2012.09.005
   PubMed Web of Science ®Google Scholar
• de Carcer G, Manning G, Malumbres M. From Plk1 to Plk5: functional evolution of polo-like kinases. Cell Cycle 2011; 10:2255-62; PMID:21654194; http://dx.doi.org/10.4161/cc.10.14.16494
   PubMed Web of Science ®Google Scholar
• Zitouni S, Nabais C, Jana SC, Guerrero A, Bettencourt-Dias M. Polo-like kinases: structural variations lead to multiple functions. Nat Rev Mol Cell Biol 2014; 15:433-52; PMID:24954208; http://dx.doi.org/10.1038/nrm3819
   PubMed Web of Science ®Google Scholar
• Grim JE, Gustafson MP, Hirata RK, Hagar AC, Swanger J, Welcker M, Hwang HC, Ericsson J, Russell DW, Clurman BE. Isoform- and cell cycle-dependent substrate degradation by the Fbw7 ubiquitin ligase. J Cell Biol 2008; 181:913-20; PMID:18559665; http://dx.doi.org/10.1083/jcb.200802076
   PubMed Web of Science ®Google Scholar
• Currie E, Schulze A, Zechner R, Walther TC, Farese RV, Jr. Cellular fatty acid metabolism and cancer. Cell Metab 2013; 18:153-61; PMID:23791484; http://dx.doi.org/10.1016/j.cmet.2013.05.017
   PubMed Web of Science ®Google Scholar
• Guo D, Bell EH, Mischel P, Chakravarti A. Targeting SREBP-1-driven lipid metabolism to treat cancer. Curr Pharm Des 2014; 20:2619-26; PMID:23859617; http://dx.doi.org/10.2174/13816128113199990486
   PubMed Web of Science ®Google Scholar
• Peck B, Schulze A. Lipid Desaturation: the next step in targeting lipogenesis in cancer? FEBS J 2016; 283:2767-78; PMID:26881388
   PubMed Web of Science ®Google Scholar
• Porstmann T, Santos CR, Lewis C, Griffiths B, Schulze A. A new player in the orchestra of cell growth: SREBP activity is regulated by mTORC1 and contributes to the regulation of cell and organ size. Biochem Soc Trans 2009; 37:278-83; PMID:19143646; http://dx.doi.org/10.1042/BST0370278
   PubMed Web of Science ®Google Scholar
• Duvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, Triantafellow E, Ma Q, Gorski R, Cleaver S, et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 2010; 39:171-83; PMID:20670887; http://dx.doi.org/10.1016/j.molcel.2010.06.022
   PubMed Web of Science ®Google Scholar
• Guo D, Prins RM, Dang J, Kuga D, Iwanami A, Soto H, Lin KY, Huang TT, Akhavan D, Hock MB, et al. EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal 2009; 2:ra82; PMID:20009104; http://dx.doi.org/10.1126/scisignal.2000446
   PubMed Web of Science ®Google Scholar
• Porstmann T, Griffiths B, Chung YL, Delpuech O, Griffiths JR, Downward J, Schulze A. PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene 2005; 24:6465-81; PMID:16007182
   PubMed Web of Science ®Google Scholar
• Porstmann T, Santos CR, Griffiths B, Cully M, Wu M, Leevers S, Griffiths JR, Chung YL, Schulze A. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab 2008; 8:224-36; PMID:18762023; http://dx.doi.org/10.1016/j.cmet.2008.07.007
   PubMed Web of Science ®Google Scholar
• Ricoult SJ, Yecies JL, Ben-Sahra I, Manning BD. Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP. Oncogene 2016; 35:1250-60; PMID:26028026; http://dx.doi.org/10.1038/onc.2015.179
   PubMed Web of Science ®Google Scholar
• Williams KJ, Argus JP, Zhu Y, Wilks MQ, Marbois BN, York AG, Kidani Y, Pourzia AL, Akhavan D, Lisiero DN, et al. An essential requirement for the SCAP/SREBP signaling axis to protect cancer cells from lipotoxicity. Cancer Res 2013; 73:2850-62; PMID:23440422; http://dx.doi.org/10.1158/0008-5472.CAN-13-0382-T
   PubMed Web of Science ®Google Scholar
• Cheng C, Ru P, Geng F, Liu J, Yoo JY, Wu X, Cheng X, Euthine V, Hu P, Guo JY, et al. Glucose-Mediated N-glycosylation of SCAP Is Essential for SREBP-1 Activation and Tumor Growth. Cancer Cell 2015; 28:569-81; PMID:26555173; http://dx.doi.org/10.1016/j.ccell.2015.09.021
   PubMed Web of Science ®Google Scholar
• Griffiths B, Lewis CA, Bensaad K, Ros S, Zhang Q, Ferber EC, Konisti S, Peck B, Miess H, East P, et al. Sterol regulatory element binding protein-dependent regulation of lipid synthesis supports cell survival and tumor growth. Cancer Metab 2013; 1:3; PMID:24280005; http://dx.doi.org/10.1186/2049-3002-1-3
   PubMedGoogle Scholar
• Lewis CA, Brault C, Peck B, Bensaad K, Griffiths B, Mitter R, Chakravarty P, East P, Dankworth B, Alibhai D, et al. SREBP maintains lipid biosynthesis and viability of cancer cells under lipid- and oxygen-deprived conditions and defines a gene signature associated with poor survival in glioblastoma multiforme. Oncogene 2015; 34:5128-40; PMID:25619842; http://dx.doi.org/10.1038/onc.2014.439
   PubMed Web of Science ®Google Scholar
• Bengoechea-Alonso MT, Ericsson J. SREBP in signal transduction: cholesterol metabolism and beyond. Curr Opin Cell Biol 2007; 19:215-22; PMID:17303406; http://dx.doi.org/10.1016/j.ceb.2007.02.004
   PubMed Web of Science ®Google Scholar
• Jeon TI, Osborne TF. SREBPs: metabolic integrators in physiology and metabolism. Trends Endocrinol Metab 2012; 23:65-72; PMID:22154484; http://dx.doi.org/10.1016/j.tem.2011.10.004
   PubMed Web of Science ®Google Scholar
• Li S, Oh YT, Yue P, Khuri FR, Sun SY. Inhibition of mTOR complex 2 induces GSK3/FBXW7-dependent degradation of sterol regulatory element-binding protein 1 (SREBP1) and suppresses lipogenesis in cancer cells. Oncogene 2016; 35:642-50; PMID:25893295; http://dx.doi.org/10.1038/onc.2015.123
   PubMed Web of Science ®Google Scholar
• Zhang Z, Chen L, Wang H, Ahmad N, Liu X. Inhibition of Plk1 represses androgen signaling pathway in castration-resistant prostate cancer. Cell Cycle 2015; 14:2142-8; PMID:25927139; http://dx.doi.org/10.1080/15384101.2015.1041689
   PubMed Web of Science ®Google Scholar
• Zhang Z, Hou X, Shao C, Li J, Cheng JX, Kuang S, Ahmad N, Ratliff T, Liu X. Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer. Cancer Res 2014; 74:6635-47; PMID:25252916; http://dx.doi.org/10.1158/0008-5472.CAN-14-1916
   PubMed Web of Science ®Google Scholar
• Fukushima H, Ogura K, Wan L, Lu Y, Li V, Gao D, Liu P, Lau AW, Wu T, Kirschner MW, et al. SCF-mediated Cdh1 degradation defines a negative feedback system that coordinates cell-cycle progression. Cell Rep 2013; 4:803-16; PMID:23972993; http://dx.doi.org/10.1016/j.celrep.2013.07.031
   PubMed Web of Science ®Google Scholar
• Hansen DV, Tung JJ, Jackson PK. CaMKII and polo-like kinase 1 sequentially phosphorylate the cytostatic factor Emi2/XErp1 to trigger its destruction and meiotic exit. Proc Natl Acad Sci U S A 2006; 103:608-13; PMID:16407128; http://dx.doi.org/10.1073/pnas.0509549102
   PubMed Web of Science ®Google Scholar
• Mailand N, Bekker-Jensen S, Bartek J, Lukas J. Destruction of Claspin by SCFbetaTrCP restrains Chk1 activation and facilitates recovery from genotoxic stress. Mol Cell 2006; 23:307-18; PMID:16885021; http://dx.doi.org/10.1016/j.molcel.2006.06.016
   PubMed Web of Science ®Google Scholar
• Moshe Y, Boulaire J, Pagano M, Hershko A. Role of Polo-like kinase in the degradation of early mitotic inhibitor 1, a regulator of the anaphase promoting complex/cyclosome. Proc Natl Acad Sci U S A 2004; 101:7937-42; PMID:15148369; http://dx.doi.org/10.1073/pnas.0402442101
   PubMed Web of Science ®Google Scholar
• Peschiaroli A, Dorrello NV, Guardavaccaro D, Venere M, Halazonetis T, Sherman NE, Pagano M. SCFbetaTrCP-mediated degradation of Claspin regulates recovery from the DNA replication checkpoint response. Mol Cell 2006; 23:319-29; PMID:16885022; http://dx.doi.org/10.1016/j.molcel.2006.06.013
   PubMed Web of Science ®Google Scholar
• Seki A, Coppinger JA, Du H, Jang CY, Yates JR, 3rd, Fang G. Plk1- and β-TrCP-dependent degradation of Bora controls mitotic progression. J Cell Biol 2008; 181:65-78; PMID:18378770; http://dx.doi.org/10.1083/jcb.200712027
   PubMed Web of Science ®Google Scholar
• Fu Z, Malureanu L, Huang J, Wang W, Li H, van Deursen JM, Tindall DJ, Chen J. Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression. Nat Cell Biol 2008; 10:1076-82; PMID:19160488; http://dx.doi.org/10.1038/ncb1767
   PubMed Web of Science ®Google Scholar
• Chen Y, Li Y, Xue J, Gong A, Yu G, Zhou A, Lin K, Zhang S, Zhang N, Gottardi CJ, et al. Wnt-induced deubiquitination FoxM1 ensures nucleus β-catenin transactivation. EMBO J 2016; 35:668-84; PMID:26912724; http://dx.doi.org/10.15252/embj.201592810
   PubMed Web of Science ®Google Scholar
• Welcker M, Clurman BE. Oncoprotein ubiquitylation: dimers, degrons, and degradation. Cell Cycle 2014; 13:1829-30; PMID:24866825; http://dx.doi.org/10.4161/cc.29325
   PubMed Web of Science ®Google Scholar
• Welcker M, Larimore EA, Swanger J, Bengoechea-Alonso MT, Grim JE, Ericsson J, Zheng N, Clurman BE. Fbw7 dimerization determines the specificity and robustness of substrate degradation. Genes Dev 2013; 27:2531-6; PMID:24298052; http://dx.doi.org/10.1101/gad.229195.113
   PubMed Web of Science ®Google Scholar
• Atilla-Gokcumen GE, Muro E, Relat-Goberna J, Sasse S, Bedigian A, Coughlin ML, Garcia-Manyes S, Eggert US. Dividing cells regulate their lipid composition and localization. Cell 2014; 156:428-39; PMID:24462247; http://dx.doi.org/10.1016/j.cell.2013.12.015
   PubMed Web of Science ®Google Scholar
• Scaglia N, Tyekucheva S, Zadra G, Photopoulos C, Loda M. De novo fatty acid synthesis at the mitotic exit is required to complete cellular division. Cell Cycle 2014; 13:859-68; PMID:24418822; http://dx.doi.org/10.4161/cc.27767
   PubMed Web of Science ®Google Scholar
• Gijs HL, Willemarck N, Vanderhoydonc F, Khan NA, Dehairs J, Derua R, Waelkens E, Taketomi Y, Murakami M, Agostinis P, et al. Primary cilium suppression by SREBP1c involves distortion of vesicular trafficking by PLA2G3. Mol Biol Cell 2015; 26:2321-32; PMID:25904332; http://dx.doi.org/10.1091/mbc.E14-10-1472
   PubMed Web of Science ®Google Scholar
• Izawa I, Goto H, Kasahara K, Inagaki M. Current topics of functional links between primary cilia and cell cycle. Cilia 2015; 4:12; PMID:26719793; http://dx.doi.org/10.1186/s13630-015-0021-1
   PubMedGoogle Scholar
• Lee KH, Johmura Y, Yu LR, Park JE, Gao Y, Bang JK, Zhou M, Veenstra TD, Yeon Kim B, Lee KS. Identification of a novel Wnt5a-CK1varepsilon-Dvl2-Plk1-mediated primary cilia disassembly pathway. EMBO J 2012; 31:3104-17; PMID:22609948; http://dx.doi.org/10.1038/emboj.2012.144
   PubMed Web of Science ®Google Scholar
• Wang G, Chen Q, Zhang X, Zhang B, Zhuo X, Liu J, Jiang Q, Zhang C. PCM1 recruits Plk1 to the pericentriolar matrix to promote primary cilia disassembly before mitotic entry. J Cell Sci 2013; 126:1355-65; PMID:23345402; http://dx.doi.org/10.1242/jcs.114918
   PubMed Web of Science ®Google Scholar
• Christova R, Oelgeschlager T. Association of human TFIID-promoter complexes with silenced mitotic chromatin in vivo. Nat Cell Biol 2002; 4:79-82; PMID:11744923; http://dx.doi.org/10.1038/ncb733
   PubMed Web of Science ®Google Scholar
• Kadauke S, Udugama MI, Pawlicki JM, Achtman JC, Jain DP, Cheng Y, Hardison RC, Blobel GA. Tissue-specific mitotic bookmarking by hematopoietic transcription factor GATA1. Cell 2012; 150:725-37; PMID:22901805; http://dx.doi.org/10.1016/j.cell.2012.06.038
   PubMed Web of Science ®Google Scholar
• Zaidi SK, Grandy RA, Lopez-Camacho C, Montecino M, van Wijnen AJ, Lian JB, Stein JL, Stein GS. Bookmarking target genes in mitosis: a shared epigenetic trait of phenotypic transcription factors and oncogenes? Cancer Res 2014; 74:420-5; PMID:24408924; http://dx.doi.org/10.1158/0008-5472.CAN-13-2837
   PubMed Web of Science ®Google Scholar
• Lee KS, Burke TR, Jr, Park JE, Bang JK, Lee E. Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy. Trends Pharmacol Sci 2015; 36:858-77; PMID:26478211; http://dx.doi.org/10.1016/j.tips.2015.08.013
   PubMed Web of Science ®Google Scholar
• McInnes C, Wyatt MD. PLK1 as an oncology target: current status and future potential. Drug Discov Today 2011; 16:619-25; PMID:21601650; http://dx.doi.org/10.1016/j.drudis.2011.05.002
   PubMed Web of Science ®Google Scholar
• Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 2010; 9:643-60; PMID:20671765; http://dx.doi.org/10.1038/nrd3184
   PubMed Web of Science ®Google Scholar
• Akhoondi S, Sun D, von der Lehr N, Apostolidou S, Klotz K, Maljukova A, Cepeda D, Fiegl H, Dafou D, Marth C, et al. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res 2007; 67:9006-12; PMID:17909001; http://dx.doi.org/10.1158/0008-5472.CAN-07-1320
   PubMed Web of Science ®Google Scholar
• Rajagopalan H, Jallepalli PV, Rago C, Velculescu VE, Kinzler KW, Vogelstein B, Lengauer C. Inactivation of hCDC4 can cause chromosomal instability. Nature 2004; 428:77-81; PMID:14999283; http://dx.doi.org/10.1038/nature02313
   PubMed Web of Science ®Google Scholar
• Seong YS, Kamijo K, Lee JS, Fernandez E, Kuriyama R, Miki T, Lee KS. A spindle checkpoint arrest and a cytokinesis failure by the dominant-negative polo-box domain of Plk1 in U-2 OS cells. J Biol Chem 2002; 277:32282-93; PMID:12034729; http://dx.doi.org/10.1074/jbc.M202602200
   PubMed Web of Science ®Google Scholar
• Hanisch A, Wehner A, Nigg EA, Sillje HH. Different Plk1 functions show distinct dependencies on Polo-Box domain-mediated targeting. Mol Biol Cell 2006; 17:448-59; PMID:16267267; http://dx.doi.org/10.1091/mbc.E05-08-0801
   PubMed Web of Science ®Google Scholar
• Blume-Jensen P, Wernstedt C, Heldin CH, Ronnstrand L. Identification of the major phosphorylation sites for protein kinase C in kit/stem cell factor receptor in vitro and in intact cells. J Biol Chem 1995; 270:14192-200; PMID:7539802; http://dx.doi.org/10.1074/jbc.270.23.14192
   PubMed Web of Science ®Google Scholar